318 related articles for article (PubMed ID: 28350565)
1. Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma Patients With or Without Neoadjuvant Chemoradiotherapy.
Noordman BJ; van Klaveren D; van Berge Henegouwen MI; Wijnhoven BPL; Gisbertz SS; Lagarde SM; van der Gaast A; Hulshof MCCM; Biermann K; Steyerberg EW; van Lanschot JJB;
Ann Surg; 2018 May; 267(5):892-897. PubMed ID: 28350565
[TBL] [Abstract][Full Text] [Related]
2. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
[TBL] [Abstract][Full Text] [Related]
3. Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing?
Ranney DN; Mulvihill MS; Yerokun BA; Fitch Z; Sun Z; Yang CF; D'Amico TA; Hartwig MG
Eur J Cardiothorac Surg; 2017 Sep; 52(3):543-551. PubMed ID: 28498967
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
[TBL] [Abstract][Full Text] [Related]
5. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
[TBL] [Abstract][Full Text] [Related]
7. Frequency of surgical resection after starting neoadjuvant chemoradiotherapy in patients with esophageal cancer: A population-based cohort study.
Borggreve AS; van Rossum PSN; Mook S; Haj Mohammad N; van Hillegersberg R; Ruurda JP
Eur J Surg Oncol; 2019 Oct; 45(10):1919-1925. PubMed ID: 30975447
[TBL] [Abstract][Full Text] [Related]
8. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial.
Omloo JM; Lagarde SM; Hulscher JB; Reitsma JB; Fockens P; van Dekken H; Ten Kate FJ; Obertop H; Tilanus HW; van Lanschot JJ
Ann Surg; 2007 Dec; 246(6):992-1000; discussion 1000-1. PubMed ID: 18043101
[TBL] [Abstract][Full Text] [Related]
9. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival.
Koen Talsma A; Shapiro J; Looman CW; van Hagen P; Steyerberg EW; van der Gaast A; van Berge Henegouwen MI; Wijnhoven BP; van Lanschot JJ; ; Hulshof MC; van Laarhoven HW; Nieuwenhuijzen GA; Hospers GA; Bonenkamp JJ; Cuesta MA; Blaisse RJ; Busch OR; ten Kate FJ; Creemers GJ; Punt CJ; Plukker JT; Verheul HM; van Dekken H; van der Sangen MJ; Rozema T; Biermann K; Beukema JC; Piet AH; van Rij CM; Reinders JG; Tilanus HW
Ann Surg; 2014 Nov; 260(5):786-92; discussion 792-3. PubMed ID: 25379850
[TBL] [Abstract][Full Text] [Related]
10. Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.
Phillips AW; Lagarde SM; Navidi M; Disep B; Griffin SM
Ann Surg; 2017 Apr; 265(4):750-756. PubMed ID: 27467444
[TBL] [Abstract][Full Text] [Related]
11. Importance of Lymph Node Response After Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Depypere L; De Hertogh G; Moons J; Provoost AL; Lerut T; Sagaert X; Coosemans W; Van Veer H; Nafteux P
Ann Thorac Surg; 2021 Dec; 112(6):1847-1854. PubMed ID: 33352178
[TBL] [Abstract][Full Text] [Related]
12. Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the Netherlands: a nationwide population-based study on patterns of care and survival.
Koëter M; van Putten M; Verhoeven RHA; Lemmens VEPP; Nieuwenhuijzen GAP
Acta Oncol; 2018 Sep; 57(9):1192-1200. PubMed ID: 29528262
[TBL] [Abstract][Full Text] [Related]
13. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
[TBL] [Abstract][Full Text] [Related]
14. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
Franko J; Voynov G; Goldman CD
Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
[TBL] [Abstract][Full Text] [Related]
15. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
[TBL] [Abstract][Full Text] [Related]
16. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
17. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
[No Abstract] [Full Text] [Related]
18. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
[TBL] [Abstract][Full Text] [Related]
19. Treatment Modalities for Esophageal Adenocarcinoma in the United States: Trends and Survival Outcomes.
Di Corpo M; Schlottmann F; Strassle PD; Nurczyk K; Patti MG
J Laparoendosc Adv Surg Tech A; 2019 Aug; 29(8):989-994. PubMed ID: 31246532
[No Abstract] [Full Text] [Related]
20. Prevalence and Prognostic Significance of Extramural Venous Invasion in Patients with Locally Advanced Esophageal Cancer.
Faiz Z; Huijgen LJW; Alqethami HJ; Burgerhof JGM; Kats-Ugurlu G; Plukker JTM
Ann Surg Oncol; 2018 Jun; 25(6):1588-1597. PubMed ID: 29611027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
